Andrew Slade has 40 years of R&D experience in biologics and small molecules, across multiple therapeutical areas, gained in both small biotech and large multinational organizations. 

Over the last 25 years he has worked almost exclusively in early phase development, focusing on GLP toxicology, IMP GMP manufacturing, regulatory submissions and Phase 1 and Phase 2 clinical studies.